Association Between Polymorphisms in HSD3B1 and UGT2B17 and Prostate Cancer Risk

Urology

Volumn 70, Issue 2, 2007, Pages 374-379

  Park, Jong Y ^a   Tanner, Jean Paul ^a   Sellers, Thomas A ^a   Huang, Yifan ^a   Stevens, Colleen K ^a   Dossett, Nicole ^a   Shankar, Ravi A ^a   Zachariah, Babu ^b   Heysek, Randy ^a   Pow Sang, Julio ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; GLUCURONOSYLTRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; CODON; CONTROLLED STUDY; FAMILY HISTORY; GENE FREQUENCY; GENETIC POLYMORPHISM; HSD3B1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UGT2B17 GENE;

ADENOCARCINOMA; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 34548388037     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.001     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts & Figures 2006 (2006), American Cancer Society, Atlanta
2. Gronberg H. Prostate cancer epidemiology. Lancet 361 (2003) 859-864
3. Hsing A.W., and Chokkalingam A.P. Prostate cancer epidemiology. Front Biosci 11 (2006) 1388-1413
4. Belanger G., Beaulieu M., Marcotte B., et al. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol Cell Endocrinol 113 (1995) 165-173
5. Ross R., Bernstein L., Judd H., et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76 (1986) 45-48
6. Hajdinjak T., and Zagradisnik B. Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: frequency of DD homozygotes increases with Gleason Score. Prostate 59 (2004) 436-439
7. Gsur A., Preyer M., Haidinger G., et al. A polymorphism in the UDP-glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 497-498
8. Park J., Chen L., Shade K., et al. Asp85tyr polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 171 (2004) 2484-2488
9. Park J., Chen L., Ratnashinge L., et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 15 (2006) 1473-1478
10. Simard J., Ricketts M.L., Gingras S., et al. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26 (2005) 525-582
11. NCBI. SNP500 Cancer. Cancer Genome Anatomy Project. Available at http://snp500cancer.nci.nih.gov, accessed February 5, 2007.
12. Chang B.L., Zheng S.L., Hawkins G.A., et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 62 (2002) 1784-1789
13. Gueraud F., and Paris A. Glucuronidation: a dual control. Gen Pharmacol 31 (1998) 683-688
14. Hsing A.W., Reichardt J.K., and Stanczyk F.Z. Hormones and prostate cancer: current perspectives and future directions. Prostate 52 (2002) 213-235
15. Eaton N.E., Reeves G.K., Appleby P.N., et al. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80 (1999) 930-934
16. Mohr B.A., Feldman H.A., Kalish L.A., et al. Are serum hormones associated with the risk of prostate cancer?. Prospective results from the Massachusetts Male Aging Study. Urology 57 (2001) 930-935
17. Heikkila R., Aho K., Heliovaara M., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86 (1999) 312-315
18. Raivio T., Santti H., Schatzl G., et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 55 (2003) 194-198
19. Schatzl G., Madersbacher S., Haitel A., et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 169 (2003) 1312-1315
20. Park J.Y., Muscat J.E., Ren Q., et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 6 (1997) 791-797
21. Green M.D., and Tephly T.R. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24 (1996) 356-363
22. Gann P.H., Hennekens C.H., Ma J., et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
23. Sunyaev S., Ramensky V., Koch I., et al. Prediction of deleterious human alleles. Hum Mol Genet 10 (2001) 591-597
24. Murata M., Warren E.H., and Riddell S.R. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 197 (2003) 1279-1289
25. Wilson III W., Pardo-Manuel de Villena F., Lyn-Cook B.D., et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84 (2004) 707-714
26. MacLeod S.L., Nowell S., Plaxco J., et al. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 7 (2000) 777-782